Chris Abell

Christopher Abell, MA, PhD, FMedSci (born 11 November 1957)[1] is a British biological chemist. As of 2013, he is a Professor of Biological Chemistry at the Department of Chemistry of the University of Cambridge and Todd-Hamied Fellow of Christ's College.

Education and career

Abell attended St John's College[1] of the University of Cambridge, gaining an MA in Natural Science (1979) and a PhD on the topic of polyketide biosynthesis under the supervision of James Staunton, FRS (1982).[2] He held a research fellowship in the laboratory of David E. Cane at Brown University, Providence, USA, studying terpene biosynthesis (1982–83).[1][2]

In 1984, Abell joined the Department of Chemistry of the University of Cambridge, successively holding the positions of demonstrator, lecturer and reader in chemical biology, and becoming Professor in Biological Chemistry in 2002.[1][2] He has held visiting professorships at the Australian National University in Canberra, University of Santiago de Compostela, University of Canterbury, Christchurch, and the Université Paul Sabatier, Toulouse.[1][2][3] He has been a fellow of Christ's College since 1986; and is the college's Todd-Hamied Fellow.[4] In 2013 he was appointed the first Director of Postdoctoral Affairs at the University of Cambridge.[5]

Research

Abell has published over 200 papers.[1] His research interests include vitamin and amino acid biosynthesis as targets for the rational design of antimicrobials; fragment-based approaches to enzyme inhibition; bacterial and plant riboswitches; reactions in microdroplets; and biological nanotechnology.[6]

Awards

His awards include a Research Fellowship at King's College, Cambridge, the ICI Prize in Organic Chemistry in 1992, the Hickinbottom Fellowship of the Royal Society of Chemistry, and a Yamada Science Foundation Award.[1][2] In 2008 he was the MIT Novartis Lecturer, and in 2011 was a BIC International Fellow at the University of Canterbury, Christchurch, New Zealand.[7] He was elected a Fellow of the Academy of Medical Sciences in 2012.[8]

Companies

Abell is the co-founder of several companies. In 1999, he co-founded Astex Technology Ltd, which uses fragment-based drug discovery technology to discover cancer therapeutics.[1][3] In 2001, he co-founded Akubio, which developed biosensors for detecting bacteria and viruses; it was acquired by Inverness Medical Innovations in 2008.[9] In 2010, he co-founded Sphere Fluidics to develop microdroplet technology.[10] In 2012 he co-founded Aqdot, a company developing a new microencapsulation technology.

Selected publications

Reviews

Research papers

References

External links